Stock Analysis

Arjo Full Year 2024 Earnings: EPS Beats Expectations

OM:ARJO B
Source: Shutterstock

Arjo (STO:ARJO B) Full Year 2024 Results

Key Financial Results

  • Revenue: kr11.3b (up 2.8% from FY 2023).
  • Net income: kr498.0m (up 3.8% from FY 2023).
  • Profit margin: 4.4% (in line with FY 2023).
  • EPS: kr1.83 (up from kr1.76 in FY 2023).
earnings-and-revenue-growth
OM:ARJO B Earnings and Revenue Growth February 3rd 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Arjo EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.7%.

Looking ahead, revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Medical Equipment industry in Sweden.

Performance of the Swedish Medical Equipment industry.

The company's shares are up 4.9% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 1 warning sign for Arjo you should know about.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About OM:ARJO B

Arjo

Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.

Undervalued with excellent balance sheet.

Community Narratives

Leading the Game with Growth, Innovation, and Exceptional Returns
Fair Value SEK 300.00|49.486999999999995% undervalued
Investingwilly
Investingwilly
Community Contributor
Why ASML Dominates the Chip Market
Fair Value €864.91|16.442% undervalued
yiannisz
yiannisz
Community Contributor
Global Payments will reach new heights with a 34% upside potential
Fair Value US$142.00|20.528% undervalued
Maxell
Maxell
Community Contributor